Latanoprost Olikla

Latanoprost, the active ingredient in Latanoprost Olikla, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension. GNH USA supplies Latanoprost Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost Olikla belongs to the prostaglandin analog class and is used to manage ocular pressure‑related conditions. - Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma.

Latanoprost Olikla may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation: transient burning or stinging. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris: gradual pigmentation change. - Dry eye sensation: mild dryness or foreign‑body feeling.

Serious or Rare Side Effects: - Intra‑ocular inflammation: uveitis or iritis requiring medical attention. - Corneal edema: swelling of the cornea that can affect vision. - Vision loss: sudden decrease in visual acuity. - Allergic reaction: swelling, itching, or rash around the eye. - Periorbital fat atrophy: loss of orbital fat tissue.

Before using Latanoprost Olikla, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: discuss potential risks with a physician. - Ocular infection: avoid use if active eye infection is present. - Contact lenses: remove lenses before instillation and wait before reinserting. - Allergies: discontinue if signs of hypersensitivity appear. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost Olikla can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent prostaglandin analog eye drops: may increase risk of ocular side effects. - Systemic carbonic anhydrase inhibitors: can diminish intra‑ocular pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: monitor combined IOP‑lowering effect. - Topical corticosteroids: may reduce efficacy of latanoprost. - Anticholinergic eye drops: observe for additive ocular irritation. - Systemic NSAIDs: watch for potential additive ocular inflammation.